Goldman Sachs’s Cellectis CLLS Stock Holding History

Goldman Sachs’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-45,000	Closed	-$204K	–	6484
2022 Q1	$204K	Buy	+45,000	New	+$248K	﹤0.01%	5875

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Goldman Sachs's CLLS Position: Q1 2023 in Review

Goldman Sachs sold out of Cellectis (CLLS) in Q1 2023, closing a stake of 18,208 shares — an estimated $38.2K sold.

Goldman Sachs first reported a position in CLLS in Q4 2015 and held it in 9 quarters. The position peaked at $1.81M in Q4 2020. 34 funds tracked by Wall St. Rank hold CLLS as of Q1 2023.

Goldman Sachs reported no remaining Cellectis position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 18,208 Cellectis shares in Q1 2023, an estimated $38.2K.
Goldman Sachs first reported a position in Cellectis in Q4 2015 and held it in 9 quarters.
Goldman Sachs's Cellectis position peaked at $1.81M in Q4 2020.
34 funds tracked by Wall St. Rank held Cellectis as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.